Omapatrilat

Omapatrilat
Systematic (IUPAC) name
(4S,7S,10aS)-5-oxo-4-{[(2S)-3-phenyl-2- sulfanylpropanoyl]amino}-2,3,4,7,8,9,10,10a-octahydropyrido[6,1-b] [1,3]thiazepine-7-carboxylic acid
Identifiers
CAS number	167305-00-2
ATC code	none
PubChem	656629
Chemical data
Formula	C19H24N2O4S2
Mol. mass	408.534 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Omapatrilat (INN) is a novel antihypertensive agent that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling.

This drug from Bristol-Myers Squibb was not approved by the U.S. Food and Drug Administration due to angioedema safety concerns.^[1]

References

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.